BR112021025491A2 - Métodos para uso de inibidores de rad51 para tratamento de câncer pancreático - Google Patents

Métodos para uso de inibidores de rad51 para tratamento de câncer pancreático

Info

Publication number
BR112021025491A2
BR112021025491A2 BR112021025491A BR112021025491A BR112021025491A2 BR 112021025491 A2 BR112021025491 A2 BR 112021025491A2 BR 112021025491 A BR112021025491 A BR 112021025491A BR 112021025491 A BR112021025491 A BR 112021025491A BR 112021025491 A2 BR112021025491 A2 BR 112021025491A2
Authority
BR
Brazil
Prior art keywords
methods
pancreatic cancer
treat pancreatic
rad51 inhibitors
rad51
Prior art date
Application number
BR112021025491A
Other languages
English (en)
Inventor
C Castro Alfredo
Cameron Mccomas Casey
Joseph VACCA
Kevin Mills
Melinda Day
Tyler Maclay
Original Assignee
Cyteir Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyteir Therapeutics Inc filed Critical Cyteir Therapeutics Inc
Publication of BR112021025491A2 publication Critical patent/BR112021025491A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

métodos para uso de inibidores de rad51 para tratamento de câncer pancreático. a presente invenção refere-se a inibidores de rad51 representados pela seguinte fórmula estrutural e a métodos para seu uso, tal como para tratar câncer pancreático.
BR112021025491A 2019-06-21 2020-06-22 Métodos para uso de inibidores de rad51 para tratamento de câncer pancreático BR112021025491A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962864861P 2019-06-21 2019-06-21
US201962895138P 2019-09-03 2019-09-03
PCT/US2020/038895 WO2020257752A1 (en) 2019-06-21 2020-06-22 Methods of using rad51 inhibitors for treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
BR112021025491A2 true BR112021025491A2 (pt) 2022-04-26

Family

ID=71528072

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025491A BR112021025491A2 (pt) 2019-06-21 2020-06-22 Métodos para uso de inibidores de rad51 para tratamento de câncer pancreático

Country Status (12)

Country Link
US (1) US12064419B2 (pt)
EP (1) EP3986402A1 (pt)
JP (1) JP2022537372A (pt)
KR (1) KR20220024857A (pt)
CN (1) CN114514023A (pt)
AU (1) AU2020296195A1 (pt)
BR (1) BR112021025491A2 (pt)
CA (1) CA3143716A1 (pt)
IL (1) IL288707A (pt)
MX (1) MX2021016049A (pt)
TW (1) TW202114662A (pt)
WO (1) WO2020257752A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11607404B2 (en) 2019-03-25 2023-03-21 Cyteir Therapeutics, Inc. Combinations of RAD51 and PARP inhibitors
TW202146014A (zh) * 2020-03-03 2021-12-16 美商賽堤爾醫療公司 靶向同源重組：新合成致死性治療範例
WO2023078271A1 (zh) * 2021-11-02 2023-05-11 上海旭成医药科技有限公司 芳香化合物、其制备方法、中间体、药物组合物和应用
WO2023211945A1 (en) * 2022-04-25 2023-11-02 Cyteir Therapeutics, Inc. Methods of using a (thiazolyl)benzenesulfonamide derivative
WO2023211938A1 (en) * 2022-04-25 2023-11-02 Cyteir Therapeutics, Inc. Methods of using a (thiazolyl)benzenesulfonamide derivative
WO2024086735A1 (en) * 2022-10-19 2024-04-25 Cyteir Therapeutics, Inc. Methods of using a (thiazolyl) benzenesulfonamide derivative
CN117603097B (zh) * 2023-11-29 2024-06-18 安徽泽升科技股份有限公司 一种快速制备2-溴-5-硝基苯磺酰氯的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
DK0834575T3 (da) 1990-12-06 2002-04-02 Affymetrix Inc A Delaware Corp Identifikation af nucleinsyrer i prøver
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
US10912761B2 (en) * 2012-11-30 2021-02-09 The University Of Chicago Methods and compositions involving RAD51 inhibitors
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
WO2017149493A1 (en) * 2016-03-02 2017-09-08 The University Of Chicago Small molecules inhibitors of rad51
MX2020000367A (es) 2017-07-11 2020-08-17 Cyteir Therapeutics Inc Inhibidores de rad51.
JP7265537B2 (ja) * 2017-09-11 2023-04-26 サイティアー セラピューティクス，インコーポレイティド Ｒａｄ５１阻害剤
JP7460649B2 (ja) 2019-03-12 2024-04-02 サイティアー セラピューティクス，インコーポレイティド Ｒａｄ５１インヒビター
US11607404B2 (en) * 2019-03-25 2023-03-21 Cyteir Therapeutics, Inc. Combinations of RAD51 and PARP inhibitors

Also Published As

Publication number Publication date
IL288707A (en) 2022-02-01
JP2022537372A (ja) 2022-08-25
KR20220024857A (ko) 2022-03-03
EP3986402A1 (en) 2022-04-27
CN114514023A (zh) 2022-05-17
MX2021016049A (es) 2022-02-03
US12064419B2 (en) 2024-08-20
WO2020257752A1 (en) 2020-12-24
AU2020296195A1 (en) 2022-01-20
US20200397760A1 (en) 2020-12-24
TW202114662A (zh) 2021-04-16
CA3143716A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
BR112021025491A2 (pt) Métodos para uso de inibidores de rad51 para tratamento de câncer pancreático
BR112021017336A2 (pt) Inibidores de rad51
CL2022001671A1 (es) Inhibidores de sos1
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
MX2020013649A (es) Composiciones y metodos para inhibir la actividad de la arginasa.
CR20190478A (es) Inhibidores de pd-1/pd-l1
PH12018500899A1 (en) Compositions and methods for inhibiting arginase activity
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
CL2015003200A1 (es) Potenciador de inhibidores del homólogo de zeste
MX2018009633A (es) Inhibidor de indoleamina-2,3-dioxigenasa (ido).
EA201591317A1 (ru) Соединения тубулизина, способы их получения и применение
NZ718055A (en) Substituted pyrimidine bmi-1 inhibitors
NZ710444A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
PH12014501365A1 (en) Compounds
EA201591497A1 (ru) Новые производные октагидропирроло[3,4-c]пиррола и их аналоги в качестве ингибиторов аутотаксина
CL2021003513A1 (es) Compuestos heterocíclicos, como inhibidores de bet; composición, útil para tratar cáncer.
UY35951A (es) HETEROARILOS y USOS DE ESTOS
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
PH12017501879A1 (en) Methods for treating cancer
CO2019000753A2 (es) Métodos para tratar el cáncer de próstata
BR112021017325A2 (pt) Combinações de inibidores de rad51 e de parp
MX2014007895A (es) Inhibidores de iap.
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами
TN2017000047A1 (en) Azetidinyloxyphenylpyrrolidine compounds